SurModics (SRDX) Tops Q3 EPS by 7c, suspends previous guidance

SurModics (NASDAQ: SRDX) reported Q3 EPS of ($0.27), $0.07 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $30.3 million versus the consensus estimate of $29.95 million.

Fiscal Year 2024 Financial Guidance

Surmodics is suspending its previously issued financial guidance for fiscal 2024 in light of the pending acquisition by GTCR.

For earnings history and earnings-related data on SurModics (SRDX) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Bernstein SocGen's Thoughts on Abbvie (ABBV) Following APGE Acquisition
• Increasing unusual put volume: AVGX WMB FJET EWA NASA BSX DFTX ACI TE BURL HSBC RIO WRBY OBDC GT DRAM